DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Advisors Asset Management Inc.

Advisors Asset Management Inc. cut its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 40.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 8,791 shares of the medical device company’s stock after selling 6,096 shares during the quarter. Advisors Asset Management Inc.’s holdings in DexCom were worth $589,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of DexCom during the 2nd quarter valued at $25,000. Sachetta LLC increased its position in shares of DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares during the period. Riverview Trust Co increased its position in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the period. DT Investment Partners LLC increased its position in shares of DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 315 shares during the period. Finally, ORG Partners LLC increased its position in shares of DexCom by 1,992.0% during the 2nd quarter. ORG Partners LLC now owns 523 shares of the medical device company’s stock valued at $59,000 after purchasing an additional 498 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 5,431 shares of company stock valued at $399,319. Insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Leerink Partners lowered their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company lifted their target price on DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Piper Sandler restated an “overweight” rating and issued a $90.00 target price on shares of DexCom in a report on Monday, August 26th. JPMorgan Chase & Co. lifted their target price on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Finally, Royal Bank of Canada decreased their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $104.59.

DexCom Price Performance

DXCM opened at $78.10 on Thursday. The stock has a market cap of $30.51 billion, a price-to-earnings ratio of 46.77, a PEG ratio of 2.38 and a beta of 1.17. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The stock has a fifty day moving average price of $71.11 and a 200 day moving average price of $88.51.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.